Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | TP53 Y220S |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| TP53 Y220S | Advanced Solid Tumor | decreased response | Rezatapopt | Preclinical - Cell culture | Actionable | In a preclinical study, Rezatapopt (PC14586) reactivated Tp53 function, inhibited proliferation, viability and colony formation, and induced cell cycle arrest and apoptosis in cells expressing TP53 Y220S with reduced potency compared to TP53 Y220C in culture (PMID: 41748563). | 41748563 |